tirzepatide liver for MASH with Fibrosis Tirzepatide Shows Improvements in MASH

Prescription drug costs top employer health concerns as GLP-1 coverage expands despite financial strain Large employers cite medication expenses as their biggest financial challenge, with many reconsidering coverage of costly GLP-1 weight loss drugs despite worker demand

Who May Consider Noom

The weight-loss market in India stands at around Rs 1,446 crore on a moving annual turnover (MAT) basis, with semaglutide-based drugs accounting for Rs 445 crore as of February 2026

Vogt, R

Motus (oral) reported notable human clinical trial results for an oral supplement, and that difference - oral versus injectable - matters for many peoples preferences and lifestyles

This type of multi-ingredient approach often yields better results than single-ingredient products, as it addresses skin brightening from multiple angles whilst providing antioxidant protection